1. Home
  2. XAIR vs CDT Comparison

XAIR vs CDT Comparison

Compare XAIR & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Beyond Air Inc.

XAIR

Beyond Air Inc.

HOLD

Current Price

$0.38

Market Cap

5.4M

Sector

Health Care

ML Signal

HOLD

CDT

Conduit Pharmaceuticals Inc.

HOLD

Current Price

$0.74

Market Cap

5.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XAIR
CDT
Founded
2011
2019
Country
United States
United States
Employees
N/A
4
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.4M
5.9M
IPO Year
2015
N/A

Fundamental Metrics

Financial Performance
Metric
XAIR
CDT
Price
$0.38
$0.74
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$10.00
N/A
AVG Volume (30 Days)
228.3K
2.6M
Earning Date
06-16-2026
04-15-2026
Dividend Yield
N/A
N/A
EPS Growth
62.09
N/A
EPS
N/A
N/A
Revenue
$3,705,000.00
N/A
Revenue This Year
$122.00
N/A
Revenue Next Year
$58.15
N/A
P/E Ratio
N/A
N/A
Revenue Growth
219.67
N/A
52 Week Low
$0.15
$0.37
52 Week High
$3.78
$11.00

Technical Indicators

Market Signals
Indicator
XAIR
CDT
Relative Strength Index (RSI) 33.65 33.48
Support Level N/A $0.49
Resistance Level $0.59 $1.22
Average True Range (ATR) 0.05 0.28
MACD -0.00 0.03
Stochastic Oscillator 3.71 2.01

Price Performance

Historical Comparison
XAIR
CDT

About XAIR Beyond Air Inc.

Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.

About CDT Conduit Pharmaceuticals Inc.

CDT Equity Inc is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. It has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments. The company's pipeline includes candidates that target autoimmune disorders, as well as idiopathic male infertility, oncology, dermatology, rare disease and animal health. It has one operating segment focused on the research and development of clinical assets.

Share on Social Networks: